Editas Medicine (EDIT) Non-Current Deffered Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Non-Current Deffered Revenue data on file, last reported at $44.5 million in Q4 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 17.89% year-over-year to $44.5 million in Q4 2025; TTM through Dec 2025 was $44.5 million, a 17.89% decrease from a year earlier, with the FY2025 full-year figure at $44.5 million, down 17.89% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $44.5 million, down from $54.2 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for EDIT reached as high as $68.9 million in Q2 2022 and fell as low as $44.5 million in Q4 2025.
• Historically, Non-Current Deffered Revenue has averaged $57.8 million across 5 years, with a median of $58.7 million in 2021.
• Across the five-year window, Non-Current Deffered Revenue sank 60.1% in 2021 and gained 24.75% in 2022, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $60.9 million in 2021, then slipped by 0.36% to $60.7 million in 2022, then changed by 0.0% to $60.7 million in 2023, then decreased by 10.65% to $54.2 million in 2024, then retreated by 17.89% to $44.5 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $44.5 million in Q4 2025, $54.2 million in Q3 2025, and $54.2 million in Q2 2025.